Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clotiazepam→

Clotiazepam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
33671-46-4
Molecular formula
C16H15ClN2OS
Molecular weight
318.8 g/mol
Drug class
Thienodiazepine anxiolyticpositive allosteric modulator of GABAA receptors
Mechanism of action
Enhances GABA-mediated inhibitory neurotransmission through positive allosteric modulation of GABAA receptor complexes at the benzodiazepine binding site, producing anxiolytic, sedative and muscle-relaxant effects.
Indications / reported uses
  • Short-term treatment of anxiety disorders in countries where clotiazepam products are authorised; not intended for long-term use because of tolerance, dependence and withdrawal risks

Sources: NLM MeSH — Clotiazepam · PubMed — Clotiazepam thienodiazepine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clotiazepam Environmental Risk Assessment (ERA) (the Clotiazepam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.